Lamivudine/zidovudine (DrugBank: Zidovudine, Lamivudine)
7 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
25 | Progressive multifocal leukoencephalopathy | 0 |
26 | HTLV-1-associated myelopathy | 0 |
94 | Primary sclerosing cholangitis | 0 |
135 | Aicardi syndrome | 0 |
265 | Lipodystrophy | 1 |
325 | Hereditary autoinflammatory syndrome | 0 |
331 | Idiopathic multicentric castleman disease | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00005764 (ClinicalTrials.gov) | May 2000 | 30/5/2000 | A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients | Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL) | HIV Infections;Lipodystrophy | Drug: Lamivudine/Zidovudine;Drug: Abacavir sulfate;Drug: Lamivudine | Glaxo Wellcome | NULL | Completed | 18 Years | N/A | Both | 100 | Phase 4 | United States |